AUAUniversity Podcast Series: Episode No. 24

Treatment For Metastatic Hormone Sensitive Prostate Cancer (M - HSPC)

Co-Host: Kelvin Moses, MD

At the conclusion of these activities, participants will be able to:
1. Identify the active agents and their mechanism of action in the management of metastatic HSPC.
2. Describe the risks and benefits of treatment for metastatic HSPC.

This educational series is supported by independent educational grants from:
Bristol-Myers Squibb
Genomic Health
Pfizer, Inc.
Sanofi Genzyme
UroGen Pharma